Journal
FRONTIERS IN IMMUNOLOGY
Volume 4, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2013.00422
Keywords
CD57; NK cells; HCMV infection; ageing; chronic infection; cancer; autoimmune diseases; T cells
Categories
Funding
- UK Medical Research Council [G1000808]
- MRC [MR/J003999/1]
- MRC [G0400225, G1000808] Funding Source: UKRI
- Medical Research Council [1264001, G0400225, G1000808] Funding Source: researchfish
Ask authors/readers for more resources
Historically, human NK cells have been identified as CD3(-)CD56(+)CD16(+/-) lymphocytes. More recently it has been established that CD57 expression defines functionally discrete sub-populations of NK cells. On T cells, CD57 expression has been regarded as a marker of terminal differentiation and (perhaps wrongly) of anergy and senescence. Similarly, CD57 expression seems to identify the final stages of peripheral NK cell maturation; its expression increases with age and is associated with chronic infections, particularly human cytomegalovirus infection. However, CD57(+) NK cells are highly cytotoxic and their presence seems to be beneficial in a number of non-communicable diseases. The purpose of this article is to review our current understanding of CD57 expression as a marker of NK cell function and disease prognosis, as well as to outline areas for further research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available